PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has dosed the first patient in a Phase 1 trial of CT-202, moving its Nectin-4 x CD3 bispecific antibody into human testing across three types of advanced solid tumors.
The open-label, dose-escalation study, NCT07545122, is evaluating CT-202 as a potential monotherapy in patients with Nectin-4-expressing recurrent, unresectable or metastatic refractory or resistant urothelial, colorectal and triple-negative breast cancers.
The trial will assess safety, tolerability, pharmacokinetics and preliminary antitumor activity. Context expects to report initial Phase 1a data in the second half of 2027.
“CT-202 is being evaluated as a potential monotherapy for patients with Nectin-4-positive tumors, where substantial unmet needs exist,” Chief Executive Officer Martin Lehr said.
CT-202 is a T cell-engaging bispecific antibody designed to target Nectin-4, a cell-surface protein frequently overexpressed in solid tumors including bladder, colorectal, lung and breast cancers.
Nectin-4 is already a clinically validated cancer target through antibody-drug conjugate therapy, which can be associated with adverse events including neuropathy and rash.
Context designed CT-202 as a pH-dependent T cell engager intended to be preferentially active within the tumor microenvironment.
The Philadelphia clinical-stage biotechnology company is developing T cell-engaging bispecific antibodies for solid tumors.
Additional information about the CT-202 trial is available at https://clinicaltrials.gov/.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.